GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO ® ELLIPTA ® (fluticasone furoate/vilanterol [FF/VI]) ...
LONDON--(BUSINESS WIRE)--GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced a submission to the European Medicines Agency (EMA) for the extended use of once-daily ...
Submission supported by pivotal CAPTAIN study demonstrating statistically significant improvement in lung function compared with the ICS/LABA, Relvar/Breo Ellipta At least 30% of asthma patients ...
Asthma remains one of the most prevalent chronic diseases in the US. 3 Although poor adherence substantially contributes to inadequate outcomes, even patients with high adherence often experience ...
Fluticasone furoate, vilanterol 100/25mcg, 200/25mcg; per inh; dry pwd for oral inh. Increased risk of asthma-related events (death, hospitalizations, intubations) with LABA monotherapy (without ICS).
The prescribed dosage for Breo Ellipta may depend on your individual treatment plan. Factors like your condition, medical history, age, and other treatments you take may affect your dosage of Breo ...
Please provide your email address to receive an email when new articles are posted on . Inhalers with a long-acting muscarinic antagonist and a long-acting beta agonist (LABA) resulted in “better ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback